Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...
Apellis drops as disappointing Syfovre sales drive Q3 miss
Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.
FiercePharma6d
Analysts point to Syfovre 'nadir' after Apellis discloses disappointing quarter
Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...
ETF Daily News2d
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $47.00 at Bank of America
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...
ETF Daily News2d
What is HC Wainwright’s Estimate for APLS FY2024 Earnings?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...
Apellis price target lowered to $47 from $61 at BofA
BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported ...
Apellis price target lowered to $40 from $65 at Oppenheimer
Oppenheimer lowered the firm’s price target on Apellis (APLS) to $40 from $65 and keeps an Outperform rating on the shares. The firm ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...